长春瑞滨联合顺铂治疗蒽环类化疗后的晚期乳腺癌疗效分析  

Effect of vinblastin combined with cisplatin in treatment of patients with advanced breast cancer

作　　者：李琳[1] 许崇安[1] 刘殊[1] 徐洁[1] 齐海燕[1] 张学梅[1] 

机构地区：[1]中国医科大学附属第四医院肿瘤内科,辽宁沈阳110032

出　　处：《现代肿瘤医学》2009年第1期51-52,共2页Journal of Modern Oncology

摘　　要：目的:观察长春瑞滨(NVB)和顺铂(DDP)联合方案治疗既往经蒽环类药物化疗失败、晚期复发转移的乳腺癌患者的疗效及不良反应。方法:NVB 25mg/m2加入生理盐水50ml静脉推注,d1,8;DDP 30mg/m2加入生理盐水250m l静脉滴注,d1-3,21天为1周期,至少用2个周期。结果:36例患者中完全缓解(CR)8.3%,部分缓解(PR)38.9%,总有效率为47.2%,主要不良反应为骨髓抑制,以白细胞减少多见,其中III-IV度骨髓抑制发生率为36.1%。结论:NVB与DDP联合化疗对蒽环类药物治疗失败的晚期乳腺癌患者有较好疗效,不良反应可以耐受,值得临床推广应用。Objective： To investigate the efficacy and toxicity of vinblastin combined with cisplatin for patients with advanced breast cancer. Methods： Thirty - six patients failured to adriamycin - based chemotherapy were treated with vinblastin and cisplatin. Vinblastin 25mg/m2 was given intravenously on d1 and ds, cisplatin 30mg/m2 intravenously was given from d1 to d3. The regimen was repeated every 21 days and the clinical response was assessed after two cycles. Results： There were 3 CR （8. 3% ） ,14 PR （38. 9% ） among 36 patients The response rate was 47.2%. The major toxicity was bone marrow depression and leukopenia. The Rates of grade 3 or 4 myelosuppression was 36.1%. Conclusion： Vinblastin combined with cisplatin is effective for advanced breast cancer patients. Toxicities are tolerable . This therapy can be used in patients failured to adriamycin - based chemotherapy.

关 键 词：长春瑞滨 顺铂 联合化疗 晚期乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]